AccessibilityHelp

Klotho Neurosciences(NASDAQ) WENA

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-99%
5 YearN/A
1 Year-79%
1 Month-61%
N/A
Klotho Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 5.792026-10-26
Klotho Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.21%USD 5.612026-10-19
1 month-60.5%USD 14.662026-09-25
3 month-41.75%USD 9.942026-07-28
Year to date-59.93%USD 14.452025-12-31
1 year-79.42%USD 28.132025-10-24
3 year-98.92%USD 534.502023-10-27
Since inception-98.83%USD 494.502022-04-29

Klotho Neurosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$195.80K

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

WENA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Klotho Neurosciences

Greenland Mines Ltd. is a diversified company engaged in natural resources and cell and gene therapy. The company focuses on exploring palladium, gold, and platinum while developing innovative therapies for neurodegenerative diseases.

Products and Services
  • Exploration of palladium, gold, and platinum resources
  • Development of KLTO-202 for ALS treatment
  • Research on therapies for Alzheimer's and Parkinson's diseases
Growth Outlook
  • Expansion of the Skaergaard project in Southeast Greenland
  • Increasing investment in gene therapy research and development
  • Potential partnerships with biotech firms for therapeutic advancements
Financial Highlights
  • Recent quarterly net income of -$3.68 million for Q2 2026
  • Cash and cash equivalents of $9.34 million as of June 30, 2026
  • Trailing twelve months (TTM) cash flow negative at -$6.56 million
Greenland Mines Ltd. operates in two distinct segments, positioning itself strategically in both the natural resources and biotechnology sectors. The company's focus on the Skaergaard project highlights its commitment to exploring valuable mineral resources, particularly in a region known for its rich deposits. On the biotechnology front, the development of KLTO-202 and other therapies addresses significant unmet medical needs, particularly in neurodegenerative diseases. Financially, the company has faced challenges, as indicated by its recent quarterly net income loss. However, it maintains a solid cash position, which may support ongoing research and operational activities. The negative cash flow reflects the high costs associated with research and development, typical for companies in the biotech sector. Overall, Greenland Mines Ltd. presents a unique investment opportunity, combining resource exploration with cutting-edge therapeutic development. The company's dual focus may appeal to investors looking for exposure to both the mining and biotechnology industries.
AI Generated • Oct 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Joseph Sinkule, PharmD

Website

greenlandmines.com

Headquarters

Omaha, NE 68144, US

WENA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.16%

Return on Capital

-10.15%

Return on Assets

6.92%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.36M

EBITDA

-$1.36M

Operating Cash Flow

-$1.18M

Capital Expenditure

-$123.50K

Free Cash Flow

-$1.30M

Cash & ST Invst.

$845.34K

Total Debt

$3.93M

Klotho Neurosciences Performance Analysis

Klotho Neurosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Klotho Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31N/A
Q22024-06-30N/A
Klotho Neurosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 4.14N/A
20232023-12-31USD -2.34N/A
20242024-12-31USD -15.98583.4%
20252025-12-31USD -10.88-31.9%
Klotho Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30289.7%
Q42023-12-31-47.9%
Q12024-03-31-239.0%
Q22024-06-30-25.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

1

N/A

Net Income

-$451.64K

-194.1%

EBITDA

-$395.61K

-62.0%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$845.34K

+583.3%

Total Debt

$3.93M

+351.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.90M

N/A

Short Term Debt

$31.00K

-97.7%

Return on Assets

6.92%

N/A

Return on Invested Capital

-7.59%

N/A

Free Cash Flow

-$548.36K

-6.8%

Operating Cash Flow

-$424.86K

+17.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMNNImunon, Inc.
$1.23-0.40%
CYADCelyad Oncology S.A.
$0.47-12.96%
PIRSPieris Pharmaceuticals, Inc.
$13.60-15.58%
NYMXFNymox Pharmaceutical Corporation
$0.04-31.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$90.50+8.30%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.98-8.54%
TQQQProShares Trust - ProShares UltraPro Qqq
$68.43+3.23%
INTCIntel
$90.47+4.04%

Questions About WENA

What is the current price of Klotho Neurosciences?

Klotho Neurosciences is trading at N/A per share.

What is the 52-week range for Klotho Neurosciences?

Over the past 52 weeks, Klotho Neurosciences has traded between N/A and N/A.

How much debt does Klotho Neurosciences have?

As of the most recent reporting period, Klotho Neurosciences reported total debt of $297.97K.

How much cash does Klotho Neurosciences have on hand?

Klotho Neurosciences reported $9.34M in cash and cash equivalents in its most recent financial results.

What is Klotho Neurosciences’s dividend yield?

Klotho Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services